|
||
© The Rockefeller University Press,
0021-9525/2000//905 $5.00
The Journal of Cell Biology, Volume 150, Number 4,
, 2000 905-912
Report |
Tyrosine Phosphorylation of Eps15 Is Required for Ligand-Regulated, but Not Constitutive, Endocytosis
pdifiore{at}ieo.it
Membrane receptors are internalized either constitutively or upon ligand engagement. Whereas there is evidence for differential regulation of the two processes, little is known about the molecular machinery involved. Previous studies have shown that an unidentified kinase substrate is required for endocytosis of the epidermal growth factor receptor (EGFR), the prototypical ligand-inducible receptor, but not of the transferrin receptor (TfR), the prototypical constitutively internalized receptor. Eps15, an endocytic protein that is tyrosine phosphorylated by EGFR, is a candidate for such a function. Here, we show that tyrosine phosphorylation of Eps15 is necessary for internalization of the EGFR, but not of the TfR. We mapped Tyr 850 as the major in vivo tyrosine phosphorylation site of Eps15. A phosphorylation-negative mutant of Eps15 acted as a dominant negative on the internalization of the EGFR, but not of the TfR. A phosphopeptide, corresponding to the phosphorylated sequence of Eps15, inhibited EGFR endocytosis, suggesting that phosphotyrosine in Eps15 serves as a docking site for a phosphotyrosine binding protein. Thus, tyrosine phosphorylation of Eps15 represents the first molecular determinant, other than those contained in the receptors themselves, which is involved in the differential regulation of constitutive vs. regulated endocytosis.
Key Words: Eps15 phosphotyrosine endocytosis epidermal growth factor receptor transferrin receptor
© 2000 The Rockefeller University Press
| Introduction |
|---|
|
|
|---|
Despite structural and molecular similarities, coated pits internalizing constitutive or ligand-inducible receptors must differ, as indicated by findings that endocytosis is a saturable process in which EGFRs compete with themselves, but not with TfRs (Hanover et al. 1984; Wiley 1988; Warren et al. 1997). It is now clear that one major difference resides in the receptors themselves. Constitutively internalized receptors continuously expose endocytic codes, which are responsible for interaction with the recruiting complex, AP2 (Nesterov et al. 1999). Ligand-induced receptors and, in particular, receptor tyrosine kinases (RTKs), possess cryptic codes that are unmasked by conformational changes after ligand engagement, receptor activation, and autophosphorylation (Nesterov et al. 1995a,Nesterov et al. 1995b). Thus, for receptors such as the EGFR, tyrosine kinase activity is required for internalization. Studies by Lamaze and Schmid 1995 demonstrated that a kinase substrate, other than the autophosphorylating receptor itself, is required for the efficient recruitment of EGFRs, but not of TfRs, into coated pits. Such a substrate might coincide with one of the several accessory proteins that are found in coated pits at substoichiometric ratios and are thought to constitute the regulatory software of the endocytic process (Pishvaee and Payne 1998; Marsh and McMahon 1999).
One such protein, Eps15, was originally identified as a substrate of the EGFR kinase (Fazioli et al. 1993) and subsequently implicated in endocytosis (Carbone et al. 1997; Benmerah et al. 1998, Benmerah et al. 1999). Eps15 is endowed with multiple binding activities. Through its COOH-terminal portion, it binds to the
subunit of the AP2 complex. In addition, the presence of three copies of the EH protein–protein interaction domain allows Eps15 to establish multiple interactions with endocytic/sorting proteins, including Epsin (Salcini et al. 1997; Chen et al. 1998). Eps15 is recruited to the plasma membrane upon EGFR activation (Torrisi et al. 1999) and localizes to coated pits (Tebar et al. 1996). In this study, we demonstrate that tyrosine phosphorylation of Eps15 is required for EGFR, but not for TfR, internalization. Thus, tyrosine phosphorylation of Eps15 constitutes the first example of a molecular event, affecting the endocytic machinery, which is involved in the differential regulation of ligand-induced and constitutive internalization.
| Materials and Methods |
|---|
|
|
|---|
Mammalian Expression Vectors
An HA-tagged Eps15 (HA-Eps15) under the transcriptional control of the CMV promoter was generated by subcloning a fragment of the mouse Eps15 cDNA, obtained by PCR and encompassing positions 2–897, in the pcDNA-1-HA vector (a generous gift of S. Gutkind, National Institutes of Health, Bethesda, MD). Individual Tyr
Phe mutations were generated by recombinant PCR, followed by swapping of the appropriate fragments in the HA-Eps15 vector, to yield the HA-Y850F vector and the other vectors harboring mutations at Tyr 19, 22, 23, and 525. Wild-type Eps15 and the Y850F mutant were also cloned in the pEGFP vector (Clontech), to generate the GFP-fusion proteins GFP-Eps15 and GFP-Y850F. Details of the engineering strategies and sequences of the oligonucleotides used are available upon request. All fragments obtained by PCR were sequence-verified.
Transfection, Microinjection, and Biochemical Assays
B82L (a kind gift of G.N. Gill, University of California, San Diego, School of Medicine, La Jolla, CA) and Cos-7 cells were transfected with lipofectamine (GIBCO BRL) or by DEAE-dextran methods, respectively. For microinjection experiments CV-1 cells were processed as described previously (Carbone et al. 1997). Peptides were microinjected in the cytoplasm of the cells at a concentration of 800 µM.
Immunoprecipitation, immunoblotting and coimmunoprecipitations were performed as previously described (Salcini et al. 1997).
mAbs used were: a commercial antiphosphotyrosine (Upstate Biotech), an anti-
-adaptin (Sigma-Aldrich), the anti-EGFR mAb-1 (Oncogene Science), and the anti-HA 12CAS. A polyclonal anti-Numb serum (Salcini et al. 1997) was also used.
EGF and transferrin internalization assays were performed as previously described (Carbone et al. 1997). In brief, 24 h after transfection, cells were serum-starved for 16 h and then incubated for 1 h at 4°C with rhodamine-EGF (R-EGF, 500 ng/ml). Cells were then shifted to 37°C for 10 min to allow internalization. For transferrin internalization, cells were incubated in serum-free medium for 3 h and then with R-Tf (50 µg/ml) for 30 min at 37°C.
Immunofluorescence and Confocal Microscopy
Cells transfected with GFP-Eps15 or GFP-Y850F were fixed with 4% formaldehyde, followed by permeabilization with 0.1% Triton X-100. After blocking with 10% normal goat serum, cells were stained with anti-EGFR or mounted directly for confocal analysis. Cells transfected with HA-Eps15 or HA-Y850F cDNAs were similarly processed and stained with anti-HA antibodies. Bound antibodies were visualized with anti-mouse IgG-Cy3 (EGFR) or anti-mouse IgG-FITC (HA). Nuclear counterstaining was performed with DAPI (Sigma-Aldrich). Coverslips were analyzed with a Zeiss Axiophot epifluorescence microscope or a BioRad MRC 1024 confocal microscope. Images were processed using the Adobe PhotoShop software.
Electron Microscopy
For immunoelectron microscopy, 10% gelatin-embedded, 2.3 M sucrose-infused blocks of aldehyde-fixed growing B82L cells, transfected with either HA-Eps15 or HA-Y850F cDNAs, were frozen in liquid nitrogen. Ultra thin cryosections were obtained with a Reichert-Jung Ultracut E with FC4E cryoattachment and collected on copper formvar carbon-coated grids. Double immunogold localizations on ultrathin cryosections were performed as previously described (Schiaffino et al. 1999). In particular, sections were immunostained with mouse monoclonal anti-hEGFR (AB-5, Oncogene Science) or goat anti-hTfR (CD71 K-20, Santa Cruz Biotechnology, Inc.) antibodies, followed by appropriate rabbit anti–mouse or rabbit anti–goat bridging antibodies and 10-nm protein A–gold. After incubation with 1% glutaraldehyde in 0.1 M sodium phosphate buffer, to quench free antibody protein A binding sites, the sections were challenged with rabbit anti-HA antibody (Santa Cruz Biotechnology, Inc.), followed by 15-nm protein A–gold. Control sections were incubated with an unrelated antibody, or without primary antibodies. To determine quenching efficiency, sections incubated with anti-EGFR or anti-TfR antibodies were quenched with 1% glutaraldehyde, in 0.1 M sodium phosphate buffer, and challenged with protein A. In all control sections, low levels of labeling were detected (not shown). Sections were examined with Zeiss EM 902 or EM10C electron microscopes.
| Results |
|---|
|
|
|---|
|
Phe mutants was indistinguishable from that of wild-type Eps15 (not shown). We concluded that Tyr 850 is the major tyrosine phosphorylation site in Eps15.
Lack of Phosphorylation Does Not Alter the Binding and Routing Properties of Eps15
Eps15 is endowed with multiple binding properties (reviewed in Santolini et al. 1999). We tested whether interactions established by Eps15 were affected by its phosphorylation status. The Y850F mutant retained intact abilities to bind to AP2 (Fig. 2 A) and to Numb, an EH-binding protein (Fig. 2 B), indicating that the mutation did not affect in a major way the conformation of the protein.
|
|
EM analysis of the distribution of the EGFR in endocytic compartments, in HA-Y850F vs. HA-Eps15 transfectants, further confirmed the block in EGFR internalization and provided insight as to the mechanisms involved. In both transfectants, EGFRs were comparably recruited to coated pits, once cells loaded with EGF at 4°C were allowed to undergo endocytosis by temperature shift at 37°C for two minutes (Fig. 4 A). However, whereas EGFRs in HA-Eps15 transfectants were able to progress to the intracellular stations of the endocytic route (coated vesicles and endosomes), they were severely impaired in doing so in HA-Y850F transfectants (Fig. 4B and Fig. C). Thus, it appears as if the block in EGFR endocytosis induced by the HA-Y850F mutant is at a level subsequent to the recruitment of the receptor in the forming pit.
|
|
| Discussion |
|---|
|
|
|---|
Our results, however, show that tyrosine phosphorylation of Eps15 is required exclusively in the process of ligand-induced receptor internalization. Two hypotheses allow to reconcile this observation with previous findings. It is possible that Eps15 is endowed with a dual function: one connected with the protein itself that is of general relevance to endocytosis, and one connected with its tyrosine phosphorylation that is specific for the internalization of RTKs. Alternatively, there may be just one function that is optimized by tyrosine phosphorylation when there is need for efficient removal of receptors from the surface, as it might be required after ligand stimulation.
What is the role of tyrosine phosphorylation of Eps15? Our results allow us to exclude that this posttranslational modification is required for any of the known protein–protein interactions of Eps15. Furthermore, tyrosine phosphorylation does not seem to be required for proper relocalization of Eps15 to the plasma membrane, or for its targeting to coated pits. Finally, it appears that phosphorylation-impaired mutants of Eps15 do not interfere with EGFR recruitment to pits, but rather with subsequent phases of the internalization process. Thus, the point of action of phospho-Eps15 might be at the level of vesiculation. Such a function could be linked to the scaffolding properties of Eps15, and possibly to the function of dynamin, as indirectly suggested by the localization of Eps15 at the rim of coated pits (Tebar et al. 1996); also, by the site of dynamin localization and by our findings of genetic interaction between the C. elegans homologues of dynamin and Eps15 (Salcini, A.E., P.P. Di Fiore, and P. Bazzicalupo, unpublished results).
While the molecular mechanisms of action of phospho-Eps15 remain to be clarified, an interesting avenue of investigation is opened by our findings that tyrosine phosphorylation of Eps15 might create a docking site for an as yet unidentified pY-binding protein. Many SH2- or PTB/PID-containing proteins are recruited to the EGFR after receptor activation, some of which have also been implicated in endocytosis (Okabayashi et al. 1996; Wang and Moran 1996; Wang et al. 1996; Sanchez et al. 1998). The identification of binding partners for phospho-Eps15 might help to elucidate the exact molecular mechanism(s) through which Eps15 regulates the endocytic process.
| Acknowledgments |
|---|
This work was supported by grants from Associazione Italiana Ricerca sul Cancro, Istituto Superiore della Sanita' (AIDS 1999), Telethon-Italy (Grant No. D.90), Consiglio Nazionale delle Ricerche (CNR; Target project Biotechnology), and the Ministry of University and Scientific and Technological Research (MURST); from the Armenise-Harvard Foundation to P.P. Di Fiore, and from Telethon-Italy (Grant No. E0942), CNR (Target project Biotechnology), and MURST to C. Tachetti. S. Confalonieri is the recipient of a fellowship from FIRC, the Fondazione Italiana Ricerca sul Cancro.
Submitted: 11 May 2000
Revised: 20 June 2000
Accepted: 27 June 2000
Abbreviations used in this paper: EGFR, epidermal growth factor receptor; RTKs, receptor tyrosine kinases; Tf, transferrin; TfR, transferrin receptor.
| References |
|---|
|
|
|---|
Benmerah A. Gagnon J. Begue B. Megarbane B. Dautry-Varsat A. Cerf-Bensussan N. The tyrosine kinase substrate eps15 is constitutively associated with the plasma membrane adaptor AP-2, J. Cell Biol, 131, 1995, 1831–1838.
Benmerah A. Lamaze C. Begue B. Schmid S.L. Dautry-Varsat A. Cerf-Bensussan N.. AP-2/Eps15 interaction is required for receptor-mediated endocytosis, J. Cell Biol, 140, 1998, 1055–1062.
Benmerah A. Bayrou M. Cerf-Bensussan N. Dautry-Varsat A.. Inhibition of clathrin-coated pit assembly by an Eps15 mutant, J. Cell Sci, 112, 1999, 1303–1311.[Abstract]
Carbone R. Fre S. Iannolo G. Belleudi F. Mancini P. Pelicci P.G. Torrisi M.R. Di Fiore P.P.. eps15 and eps15R are essential components of the endocytic pathway, Cancer Res, 57, 1997, 5498–5504.
Chen H. Fre S. Slepnev V.I. Capua M.R. Takei K. Butler M.H. Di Fiore P.P. De Camilli P.. Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis, Nature, 394, 1998, 793–797.[Medline]
Cupers P. Jadhav A.P. Kirchhausen T.. Assembly of clathrin coats disrupts the association between Eps15 and AP-2 adaptors, J. Biol. Chem, 273, 1998, 1847–1850.
Dickson R.B. Hanover J.A. Willingham M.C. Pastan I.. Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis, Biochemistry, 22, 1983, 5667–5674.[Medline]
Fazioli F. Minichiello L. Matoskova B. Wong W.T. Di Fiore P.P.. eps15, a novel tyrosine kinase substrate, exhibits transforming activity, Mol. Cell. Biol, 13, 1993, 5814–5828.
Gorman R.M. Poretz R.D.. Resolution of multiple endosomal compartments associated with the internalization of epidermal growth factor and transferrin, J. Cell Physiol, 131, 1987, 158–164.[Medline]
Hanover J.A. Willingham M.C. Pastan I.. Kinetics of transit of transferrin and epidermal growth factor through clathrin-coated membranes, Cell, 39, 1984, 283–293.[Medline]
Iannolo G. Salcini A.E. Gaidarov I. Goodman O.B. Jr. Baulida J. Carpenter G. Pelicci P.G. Di Fiore P.P. Keen J.H.. Mapping of the molecular determinants involved in the interaction between eps15 and AP-2, Cancer Res, 57, 1997, 240–245.
Jackle S. Runquist E.A. Miranda-Brady S. Havel R.J.. Trafficking of the epidermal growth factor receptor and transferrin in three hepatocytic endosomal fractions, J. Biol. Chem, 266, 1991, 1396–1402.
Kirchhausen T.. Adaptors for clathrin-mediated traffic, Annu. Rev. Cell Dev. Biol, 15, 1999, 705–732.[Medline]
Lamaze C. Schmid S.L.. Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase, J. Cell Biol, 129, 1995, 47–54.
Marsh M. McMahon H.T.. The structural era of endocytosis, Science, 285, 1999, 215–220.
Nesterov A. Kurten R.C. Gill G.N.. Association of epidermal growth factor receptors with coated pit adaptins via a tyrosine phosphorylation-regulated mechanism, J. Biol. Chem, 270, 1995, 6320–6327a.
Nesterov A. Wiley H.S. Gill G.N.. Ligand-induced endocytosis of epidermal growth factor receptors that are defective in binding adaptor proteins, Proc. Natl. Acad. Sci. USA, 92, 1995, 8719–8723b.
Nesterov A. Carter R.E. Sorkina T. Gill G.N. Sorkin A.. Inhibition of the receptor-binding function of clathrin adaptor protein AP-2 by dominant-negative mutant mu2 subunit and its effects on endocytosis, EMBO (Eur. Mol. Biol. Organ.) J, 18, 1999, 2489–2499.[Medline]
Okabayashi Y. Sugimoto Y. Totty N.F. Hsuan J. Kido Y. Sakaguchi K. Gout I. Waterfield M.D. Kasuga M.. Interaction of Shc with adaptor protein adaptins, J. Biol. Chem, 271, 1996, 5265–5269.
Pishvaee B. Payne G.S.. Clathrin coatsthreads laid bare, Cell, 95, 1998, 443–446.[Medline]
Robinson M.S.. The role of clathrin, adaptors and dynamin in endocytosis, Curr. Opin. Cell Biol, 6, 1994, 538–544.[Medline]
Salcini A.E. Confalonieri S. Doria M. Santolini E. Tassi E. Minenkova O. Cesareni G. Pelicci P.G. Di Fiore P.P.. Binding specificity and in vivo targets of the EH domain, a novel protein–protein interaction module, Genes Dev, 11, 1997, 2239–2249.
Sanchez P. De Carcer G. Sandoval I.V. Moscat J. Diaz-Meco M.T.. Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62, Mol. Cell. Biol, 18, 1998, 3069–3080.
Santolini E. Salcini A.E. Kay B.K. Yamabhai M. Di Fiore P.P.. The EH network, Exp. Cell Res, 253, 1999, 186–209.[Medline]
Schiaffino M.V. d'Addio M. Alloni A. Baschirotto C. Valetti C. Cortese K. Puri C. Bassi M.T. Colla C. De Luca M.. Ocular albinismevidence for a defect in an intracellular signal transduction system, Nat. Genet, 23, 1999, 108–112.[Medline]
Seaman M.N. Burd C.G. Emr S.D.. Receptor signalling and the regulation of endocytic membrane transport, Curr. Opin. Cell Biol, 8, 1996, 549–556.[Medline]
Tebar F. Sorkina T. Sorkin A. Ericsson M. Kirchhausen T.. Eps15 is a component of clathrin-coated pits and vesicles and is located at the rim of coated pits, J. Biol. Chem, 271, 1996, 28727–28730.
Torrisi M.R. Lotti L.V. Belleudi F. Gradini R. Salcini A.E. Confalonieri S. Pelicci P.G. Di Fiore P.P.. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalization, Mol. Biol. Cell, 10, 1999, 417–434.
Wang Z. Moran M.F.. Requirement for the adapter protein GRB2 in EGF receptor endocytosis, Science, 272, 1996, 1935–1939.[Abstract]
Wang Z. Tung P.S. Moran M.F.. Association of p120 ras GAP with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation, Cell. Growth Differ, 7, 1996, 123–133.[Abstract]
Warren R.A. Green F.A. Enns C.A.. Saturation of the endocytic pathway for the transferrin receptor does not affect the endocytosis of the epidermal growth factor receptor, J. Biol. Chem, 272, 1997, 2116–2121.
Wiley H.S.. Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system, J. Cell Biol, 107, 1988, 801–810.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|